To give life back to cancer patients
Our vision is to grow as an innovative pharmaceutical company specialized in the development of novel cancer therapies, to give life back into the hands of the patients.
Dr. Andreas Dzung
Andreas Dzung studied pharmaceutical sciences at the ETH Zurich and holds a PhD in cancer research which he obtained at the University Hospital of Zurich. Andreas has gained experience in both translational research and clinical research in dermatology with specialization in melanoma. Andreas enjoys entrepreneurship and has been able to attract the attention of investors. Write to us, if you would like to get in touch with Andreas.
Dr. Ossia Eichhoff
Ossia Eichhoff studied Biochemistry and holds a PhD in cancer research from the ETH Zürich. She has more than 15 years of experience in biomedical research and worked several years as a group leader in the pharmaceutical industry. Ossia's scientific passion is to develop novel therapeutic options for advanced melanoma patients.
Dr. Annalisa Saltari
Leading Scientist-Inflammatory skin diseases
Annalisa Saltari studied biomedical sciences and holds a PhD in molecular and regenerative medicine. She developed sucessfully several skin reconstruction models and has an expertise in both, melanoma and inflammatory skin diseases.
Prof. Mitch Levesque
Mitch Levesque is associate professor of translational dermato-oncology at the University of Zurich and Scientific Department Leader in the Department of Dermatology at the University Hospital Zurich. He has over 20 years of experience in experimental biology, and he is head of the University Research Priority Program (URPP) translational cancer biobank.
Prof. Reinhard Dummer
Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a globabl key opinion leader in dermato-oncology. Currently, he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology.